NewAmsterdam Pharma Company N.V. Ordinary Shares
$22.49
$0.56 (+2.55%)
$21.29Day Range$22.50
Key Statistics
Market Cap
$2.69B
Shares Outstanding
119.5M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Nov 23, 2022
Round Lot
100
Locale
US
Trading Data
Day Open
$21.62
Day High
$22.50
Day Low
$21.29
Volume
2.08M
VWAP
$22.14
Prev Close
$21.93
Transactions
--
Acc. Volume
--
About NewAmsterdam Pharma Company N.V. Ordinary Shares
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.
PHARMACEUTICAL PREPARATIONSSIC 2834100 employeesGOOIMEER 2-35, NARRDEN, P7, 1411 DC35 206 2971IPO Nov 23, 2022US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001936258
- Ticker Root
- NAMS
- SIC Code
- 2834
About NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) Stock
NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) closed the 2026-09-18 session at $22.49, up 2.55% versus the previous close (+0.56). The stock opened at $21.62 and traded between $21.29 and $22.50 during that session. Session trading volume was 2.1M shares. The volume-weighted average price (VWAP) is $22.14.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.
NewAmsterdam Pharma Company N.V. Ordinary Shares has a market capitalization of $2.69 billion. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. NAMS is listed on the XNAS exchange. The company employs approximately 100 people. NewAmsterdam Pharma Company N.V. Ordinary Shares is headquartered in NARRDEN, P7. The recorded listing date is 2022-11-23.
On this page you can find market NAMS stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.